hydroxyurea has been researched along with Oligodendroglioma in 2 studies
Oligodendroglioma: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs." | 2.73 | Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. ( Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reardon, DA | 2 |
| Desjardins, A | 2 |
| Vredenburgh, JJ | 2 |
| Herndon, JE | 2 |
| Coan, A | 1 |
| Gururangan, S | 2 |
| Peters, KB | 1 |
| McLendon, R | 1 |
| Sathornsumetee, S | 2 |
| Rich, JN | 2 |
| Lipp, ES | 1 |
| Janney, D | 1 |
| Friedman, HS | 2 |
| Quinn, JA | 1 |
| Friedman, AH | 1 |
| McLendon, RE | 1 |
| Provenzale, JM | 1 |
| Sampson, JH | 1 |
| Dowell, JM | 1 |
| Salvado, A | 1 |
2 trials available for hydroxyurea and Oligodendroglioma
| Article | Year |
|---|---|
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamide | 2007 |